Skip to content. | Skip to navigation


Personal tools

Dr. Peter Watson, MB BChir FRCPC

Peer-Reviewed Papers

2014

  • Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarin M,Twumasi-Boateng K, Watson PH, Holt RA, Nelson BH. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res. 2014 Mar 1;20(5):1125-34. doi: 10.1158/1078-0432.CCR-13-2147.Epub 2013 Dec 9. [PubMed - 24323902]


2013

  •  Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC. Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC). Ann Oncol. 2013 Apr 11 PMID: 23579816
  • Le Page C, Köbel M, Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarova DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L,  McAlpine JN, Matte I, Piché A, Shaw P, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM. Specimen quality evaluation from Canadian Biobanks participating in the COEUR repository. Biopreservation and Biobanking April 2013, 11(2): 83-93.2013 

  • Leblanc J, Dee S, Braun L, Daudt H, Cheah S, Watson PH. Impact of a ‘Permission to Contact’ (PTC) Platform on Biobank Enrolment and Efficiency Biopreservation and Biobanking June 2013, 11(3): 144-148. doi:10.1089/bio.2013.0004  
  • West NR, Murray JI, Watson PH. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell- like differentiation in breast cancer. Oncogene. 2013 Apr 15. doi: 10.1038/onc.2013.105. [Epub ahead of print] PMID:23584474 

  • Cheah S, O’Donoghue S, Daudt H, Dee S, LeBlanc J, Bruan L, Barens R, Vercauteren S, Boone RH, Watson PH. Permission to Contact’ (PTC) – a strategy to enhance patient engagement in translational research. Biopreservation and Biobanking 11 (4) 245-252, August 2013 

  • Hewitt R, Watson PH. Defining Biobank. Biopreservation and Biobanking, 11 (5),: 309-315, Oct 2013 

  • Watson PH. et al, A Framework for Biobank Sustainability. Biopreservation and Biobanking, in press Dec 2013  

  • Webb JR, Milne K, Watson PH, Deleeuw RJ, Nelson BH, Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2013 Nov 4. [Epub ahead of print] PMID 24190978

  • Wick D, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarnin M, Twusmasi-Boateng K, Watson PH, Holt R, Nelson BH. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clinical Cancer Research, in press Dec 2013.

  • R.O. Barnes, Albert M., Damaraju, S., De Sousa-Hitzler J., Kodeeswaran S., Mes-Masson A-M. Schacter B, Watson P. Generating a Comprehensive Set of Standard Operating Procedures for a Biorepository Network—The CTRNet Experience. Biopreservation and Biobanking 11 (6): 387-396, Jan 2013. DOI: 10.1089/bio.2013.0061 

 

2012

  • Nathan R. West, Sara E. Kost, Spencer D. Martin, Katy Milne, Ronald J. deLeeuw, Brad H. Nelson, and Peter H. Watson   Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor negative breast cancer. Br.J.Cancer. Oct 2012  [PubMed -23169287]
  • Jaeline E. Spowart1,2,3, Katelin N. Townsend1,2, Hassan Huwait4, Sima Eshragh5, Nathan R. West1,2, Steve Kalloger5, Michael Anglesio5, Robert N. Young3,6, Sharon Gorski3,7, Peter H. Watson1,2,5, C. Blake Gilks5, David G. Huntsman8, Julian J. Lum1,2,3. The Autophagy Protein LC3A Correlates with Hypoxia and is a Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer. J Pathology. In press Aug 2012.  [PubMed -22926683]

  • Cole A, Cheah S, Dee S, Hughes S, Barnes R, Watson PH Biospecimen Use and Emerging Techniques in Cancer Research. Biopreservation and Biobanking In press Aug 2012
  • Cheah S, Dee S,Cole A, Matzke L,O’Donoghue S, Watson PH. An Online Tool for Improving Biospecimen Data Element Reporting. Biopreservation and Biobanking in press July 2012
  • L.A. Matzke, S. O’Donoghue, R.O. Barnes, H. Daudt, S. Cheah, A. Suggitt, J. Bartlett, S. Damaraju, R. Johnston, L. Murphy, L. Shepherd, A.M. Mes-Masson, B. Schacter, Watson P. Certification for Biobanks: The Program Developed by the Canadian Tumour Repository Network (CTRNet). Biopreservation and Biobanking 10 (5): 426-432. October 2012.
  • Anna L. Stratford, Kristen Reipas, Kaiji Hu, Abbas Fotovoti, Peter Watson and Sandra E. Dunn. Targeting p90 ribosomal S6 kinase (RSK) eliminates tumor-initiating cells by inactivating Y-box binding protein-1 (YB-1) in triple-negative breast cancers. Stem Cells. 2012, Jul;30(7):1338-48. [PubMed -22674792]
  • Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH. CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. Clin Cancer Res. 2012 Jun 15;18(12):3281-92. Epub 2012 May 2.  [PubMed -22553348]
  • West NR, Murphy LC, Watson PH. Oncostatin-M downregulates ER in human breast cancer. Endocrine Related Cancer. Epub Jan 20th 2012  [PubMed -22267707]
  • O'Doherty K, Ibrahim T, Hawkins A, Burgess M, Watson PH. Managing the Introduction of Biobanks to Potential Participants: Lessons from a Deliberative Public Forum. Biopreservation and Biobanking, 10 (1),: 12-21. February 2012
  • Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012 Jun 21;486(7403):346-52. [PubMed -22522925] 
  • Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers.Nature. 2012 Apr 4;486(7403):395-9. doi: 10.1038/nature10933. [PubMed -22495314] 

2011

  • Watson PH, Barnes RO. A proposed schema for classifying human research biobanks, Biopreservation and Biobanking. December 2011, 9(4): 327-333.
  • Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012 Feb;22(2):299-306. Epub 2011 Oct 18. [PubMed -22009989] 
  • West, N.R., Milne, K., Truong P, Macpherson N, Nelson, B.H., Watson, P.H. Tumor infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011 Dec 8;13(6):R126. [Epub ahead of print]  [PubMed -22151962] 
  • West NR, Panet-Raymond V, Truong PT, Alexander C, Milne K, Ross LA, Loken S, Watson PH. Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR). Breast Cancer (Auckl). 2011; 5:105-15. Epub. 2011 May 31 [PubMed - 21695097]
  • Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield E, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson PH, Weier HU, Zhu C, Vaught J. Biospecimen Reporting for Improved Study Quality (BRISQ). J Proteome Res. 2011 May 16.  [PubMed -21574648] (also published in Cancer Cytopathol. 2011 Apr 25;119(2):92-101. [PubMed -21433001]  and Biopreservation and Biobanking. 2011 Apr;9(1):57-70. [PubMed -21826252] 

2010

  • Shevaun E. Hughes, Rebecca O. Barnes, Peter H. Watson.  Biospecimen Use in Cancer Research Over Two Decades.   Biopreservation and Biobanking. June 2010, 8(2): 89-97.  

  • West NR, Watson PH. S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene. 2010 Jan 18. (2010). [View Abstract - PubMed 20101226]

2009

  • Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, Tomes L, Young TL, Leygue E, Myal Y. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch. 454(6):647-56. Epub 2009 Apr 23. (2009). [View Abstract - PubMed 19387682]
  • Hewitt R, Watson PH, Dhir R, Aamodt R, Thomas G, Mercola D, Grizzle WE, Morente MM. Timing of consent for the research use of surgically removed tissue: is postoperative consenting acceptable? Cancer. 115(1):4-9. (2009). [View Abstract - PubMed 19090013]
  • Leon R, Murray JI, Cragg G, Farnell B, West NR, Pace TC, Watson PH, Bohne C, Boulanger MJ, Hof F. Identification and characterization of binding sites on S100A7, a participant in cancer and inflammation pathways. Biochemistry. 48(44):10591-600. (2009). [View Abstract - PubMed 19810752]
  • Martin ML, Wall EM, Sandwith E, Girardin A, Milne K, Watson PH, Nelson BH. Density of tumour stroma is correlated to outcome after adoptive transfer of CD4(+) and CD8 (+) T cells in a murine mammary carcinoma model. Breast Cancer Res Treat. 2009 Sep 30. (2009). [View Abstract - PubMed 19789976]
  • Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009 Jul 29;4(7):e6412. (2009). [View Abstract - PubMed 19641607]
  • Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 461(7265):809-13. (2009). [View Abstract - PubMed 19812674]
  • Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Troup S, Begic S, Parisien M, Watson PH, Murphy LC. Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat. 118(3):443-53. Epub 2008 Dec 23. (2009). [View Abstract - PubMed 19104930]
  • Turashvili G, McKinney S, Martin L, Gelmon KA, Watson P, Boyd N, Aparicio S. Columnar cell lesions, mammographic density and breast cancer risk. Breast Cancer Res Treat. 115(3):561-71. Epub 2008 Jun 28. (2009). [View Abstract - PubMed 18587641]
  • Watson PH, Wilson-McManus JE, Barnes RO, Giesz SC, Png A, Hegele RG, Brinkman JN, Mackenzie IR, Huntsman DG, Junker A, Gilks B, Skarsgard E, Burgess M, Aparicio S, McManus BM. Evolutionary concepts in biobanking - the BC BioLibrary. J Transl Med. 2009 Nov 12;7:95. (2009). [View Abstract - PubMed 19909513] 
  • West NR, Farnell B, Murray JI, Hof F, Watson PH, Boulanger MJ. Structural and functional characterization of a triple mutant form of S100A7 defective for Jab1 binding. Protein Sci. 18(12):2615-23. (2009). [View Abstract - PubMed 19844956]
  • Wolf R, Voscopoulos C, Winston J, Dharamsi A, Goldsmith P, Gunsior M, Vonderhaar BK, Olson M, Watson PH, Yuspa SH. Highly homologous hS100A15 and hS100A7 proteins are distinctly expressed in normal breast tissue and breast cancer. Cancer Lett. 277(1):101-7. Epub 2009 Jan 10. (2009). [View Abstract - PubMed 19136201]
  • Yan Y, Skliris GP, Penner C, Chooniedass-Kothari S, Cooper C, Nugent Z, Blanchard A, Watson PH, Myal Y, Murphy LC, Leygue E. Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients. Breast Cancer Res. 11(5):R67. Epub . (2009). [View Abstract - PubMed 19740422]
  • Yang T, Martin ML, Nielsen JS, Milne K, Wall EM, Lin W, Watson PH, Nelson BH. Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. Cancer Immunol Immunother. 58(11):1865-75. Epub 2009 Apr 7. (2009). [View Abstract - PubMed 19350239]

2008

  • Barnes RO, Parisien M, Murphy LC, Watson PH. Influence of evolution in tumor biobanking on the interpretation of translational research. Cancer Epidemiol Biomarkers Prev. 17(12):3344-50. (2008). [View Abstract - PubMed 19064549]
  • Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Kobel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One. 3(10):e3409. Epub 2008 Oct 15. (2008). [View Abstract - PubMed 18923710]
  •  Skliris GP, Hube F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, Murphy LC, Leygue E, Myal Y. Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology. 52(3):355-69. (2008). [View Abstract - PubMed 18269587]
  • Turashvili G, Hayes M, Gilks B, Watson P, Aparicio S. Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch. 452(6):589-98. Epub 2008 Apr 24. (2008). [View Abstract - PubMed 18437416]
  • Wang J, Barnes RO, West NR, Olson M, Chu JE, Watson PH. Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. Breast Cancer Res. 10(3):R51. Epub 2008 Jun 6. (2008). [View Abstract - PubMed 18534028]

2007

  • Mandal S, Curtis L, Pind M, Murphy LC, Watson PH. S100A7 (psoriasin) influences immune response genes in human breast cancer. Exp Cell Res. 313(14):3016-25. Epub 2007 Mar 30. (2007). [View Abstract - PubMed 17560571] 
  • Skliris GP, Lewis A, Emberley E, Peng B, Weebadda WK, Kemp A, Davie JR, Shiu RP, Watson PH, Murphy LC. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res Treat. 104(1):75-85. Epub 2006 Sep 29. (2007). [View Abstract - PubMed 17009105] 

  • Wall EM, Milne K, Martin ML, Watson PH, Theiss P, Nelson BH. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res. 67(13):6442-50. (2007). [View Abstract - PubMed 17616705] 

  • Yang T, Wall EM, Milne K, Theiss P, Watson P, Nelson BH. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. Clin Cancer Res. 13(23):7172-80. (2007). [View Abstract - PubMed 18056198]

2006

  • Blanchard AA, Watson PH, Shiu RP, Leygue E, Nistor A, Wong P, Myal Y. Differential expression of claudin 1, 3, and 4 during normal mammary gland development in the mouse. DNA Cell Biol. 25(2):79-86. (2006). [View Abstract - PubMed 16460231] 
  • Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology. 15(1):9-19. (2006). [View Abstract - PubMed 15669023] 
  • Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y. Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol. 2006 Jan 18;6:2. (2006). [View Abstract - PubMed 16420697] 
  • Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol. 18(11):1591-602. Epub 2006 Sep 20. (2006). [View Abstract - PubMed 16987935] 
  • Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer. 95(5):616-26. Epub 2006 Aug 1. (2006). [View Abstract - PubMed 16880783] 

  • Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res. 66(20):10162-70. (2006). [View Abstract - PubMed 17047081] 

  • Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH, Murphy LC. Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat. 100(1):23-31. Epub 2006 May 17. (2006). [View Abstract - PubMed 16705367]